021-51111890
购物车（）
sales@molnova.cn
Pipobroman
CAS No. 54-91-1
Pipobroman ( NSC25154 | Pipobroman )
产品货号. M18787 CAS No. 54-91-1
Pipobroman 是一种抗癌化合物，可能充当烷化剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 10MG | ￥109 | 有现货 |
|
| 25MG | ￥163 | 有现货 |
|
| 50MG | ￥251 | 有现货 |
|
| 100MG | ￥374 | 有现货 |
|
| 200MG | ￥533 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥166 | 有现货 |
|
生物学信息
-
产品名称Pipobroman
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Pipobroman 是一种抗癌化合物，可能充当烷化剂。
-
产品描述Pipobroman is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.
-
体外实验——
-
体内实验——
-
同义词NSC25154 | Pipobroman
-
通路Apoptosis
-
靶点Apoptosis
-
受体Others
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number54-91-1
-
分子量356.06
-
分子式C10H16Br2N2O2
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 36 mg/mL; 101.11 mM
-
SMILESBrCCC(=O)N1CCN(CC1)C(=O)CCBr
-
化学全称1,1'-(piperazine-1,4-diyl)bis(3-bromopropan-1-one)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Passamonti F, et al. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003 Sep;44(9):1483-1488.
